Pfenex, Pfizer deal

Pfizer terminated a deal with Pfenex, returning to the biotech worldwide rights to PF582, a biosimilar of ophthalmic drug Lucentis ranibizumab. In February 2015, Pfenex granted Hospira Inc. exclusi...